Fractyl Health to Present New Preclinical Data from its Rejuva® Single-Administration Smart GLP-1 Pancreatic Gene Therapy Platform at the World Congress Insulin Resistance, Diabetes and Cardiovascular Disease (WCIRDC)
Rhea-AI Summary
Fractyl Health (Nasdaq: GUTS), a metabolic therapeutics company, announced it will present new preclinical data from its Rejuva® platform at the 2024 Poster Session of the 22nd World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC). The presentation will focus on the feasibility and safety of novel endoscopic ultrasound-guided delivery of human GLP-1 pancreatic gene therapy in pigs. The session is scheduled for December 12, 2024, from 6:30 pm to 7:30 pm (PST).
The company specializes in developing new approaches to treat root causes of obesity and Type 2 Diabetes (T2D) through their single-administration Smart GLP-1 Pancreatic Gene Therapy Platform.
Positive
- Development of innovative GLP-1 pancreatic gene therapy platform targeting obesity and Type 2 Diabetes
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, GUTS gained 1.30%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
BURLINGTON, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches that treat root causes of obesity and Type 2 Diabetes (T2D), today announced it will present new preclinical data from its Rejuva platform at the 2024 Poster Session of the 22nd World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) taking place December 12-14, 2024.
Details of the session are below:
- Poster Title: Feasibility and Safety of Novel Endoscopic Ultrasound-Guided Delivery of Human GLP-1 Pancreatic Gene Therapy in Pigs
- Presentation Date & Time: Thursday, December 12, 2024, 6:30 pm - 7:30 pm (PST)
About Fractyl Health
Fractyl Health is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including obesity and T2D. Despite advances in treatment over the last 50 years, obesity and T2D continue to be rapidly growing drivers of morbidity and mortality in the 21st century. Fractyl Health’s goal is to transform metabolic disease treatment from chronic symptomatic management to durable disease-modifying therapies that target the organ-level root causes of disease. Fractyl Health is based in Burlington, MA. For more information, visit www.fractyl.com or https://twitter.com/FractylHealth.
About Rejuva
Fractyl Health’s Rejuva platform focuses on developing next-generation adeno-associated virus (AAV)-based, locally delivered gene therapies for the treatment of obesity and T2D. The Rejuva platform is in preclinical development and has not yet been evaluated by regulatory agencies for investigational or commercial use. Rejuva leverages advanced delivery systems and proprietary screening methods to identify and develop metabolically active gene therapy candidates targeting the pancreas. The program aims to transform the management of metabolic diseases by offering novel, disease-modifying therapies that address the underlying root causes of disease.
Contacts
Corporate Contact
Lisa Davidson, Chief Financial Officer
ir@fractyl.com, 781.902.8800
Media Contact
Jessica Cotrone, Corporate Communications
jcotrone@fractyl.com, 978.760.5622
Investor Contact
Stephen Jasper Gilmartin Group
stephen@gilmartinir.com, 619.949.3681
FAQ
What will Fractyl Health (GUTS) present at WCIRDC 2024?
When is Fractyl Health's (GUTS) presentation at WCIRDC 2024?
What therapeutic areas does Fractyl Health (GUTS) target with their Rejuva platform?
